Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects With Advanced Solid Tumors Expressing Somatostatin Receptors
Clinical trial NCT06840821 · RECRUITING
Trial details
- NCT number
- NCT06840821
- Sponsor
- Mainline Biosciences (Shanghai) Co., Ltd
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-05-08
- Primary completion
- 2028-07-04
- Enrollment
- 156
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.